Key points from article :
Remedium Bio has successfully raised over $2.3 million in an expanded seed round to advance its lead product, a single-injection gene therapy designed to reverse cartilage loss. The funding, led by Sherwood Ventures and supported by several other investors, will support research in collaboration with Tufts University School of Medicine. The therapy is particularly significant for osteoarthritis, a condition affecting millions worldwide, with no approved treatments capable of slowing or reversing disease progression.
Remedium’s therapy is based on fibroblast growth factor 18 (FGF18), a mechanism clinically proven to restore cartilage in a placebo-controlled trial. If successful, this therapy could transform rheumatology, a market valued at $37 billion. CEO Frank Luppino emphasized the technology’s potential not only for osteoarthritis but also for other age-related conditions lacking disease-modifying treatments. The company has attracted key medical experts to its advisory board, including Dr. Timothy McAlindon from Tufts Medical Center and Dr. Jeff Ellsworth, a pioneer in FGF18 research.
The company will present its research at the 2022 American Society of Bone and Mineral Research (ASBMR) meeting and has been selected as a finalist for the RESI Boston Innovator’s Pitch Challenge. These events will allow Remedium to showcase its novel gene therapy to leading investors and experts in the field.
